Company intelligence / Profile preview

KAI Pharmaceuticals

South San Francisco, California, United Statesamgen.com ↗

Ownership: Private
Development stage: Phase 2

Overview

KAI had reported compelling Phase 2a clinical results for KAI-4169 in secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. The company had started a second mid-stage study of the IV formulation of KAI-4169 prior to acquisition.

Therapeutic areas: Nephrology
Modalities: Novel agents
Industry: Biotech

Drug pipeline

1 asset

KAI-4169

Phase 2

Indications: Secondary hyperparathyroidism, Chronic kidney disease

Beyond the preview

Go deeper on KAI Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAI Pharmaceuticals.

Explore the full profile